Ipsen’s elafibranor recommended for use in patients with rare liver disease

Ipsen announced today that the National Institute for Health and Care Excellence (NICE) has recommended elafibranor 80mg tablets for the treatment of PBC in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA. This makes elafibranor the first medicine for PBC approved for use on the NHS in nearly a decade.

AbbVie, Genentech and GSK lead new pharma TV brand advertising in Q3 — report

New pharma brands are tapping into old tried-and-true pharma ad strategies and investing big in TV advertising, according to the latest tracking report from iSpot.tv.

October 28, 2023

Arrakis Therapeutics reduces headcount by 20%

Arrakis Therapeutics has prioritized its pipeline and reduced its headcount by about 20% this week, the biotech’s CEO said in a statement to Endpoints News.

March 2, 2024

Merck’s Keytruda receives approval greenlight from EU CHMP –

Keytruda is an anti-programmed death receptor-1 therapy that helps enhance the capability of the body’s immune system. Credit: Merck & Co. The European Medicines Agency’s

October 13, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.